Physician profile
Michelle Villa Olvera
NPI 1932102266
$2,221.87
in general payments reported to CMS, 2019-2025
32 companies · $599 in 2025
The $599 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $44.84 · 2021: $87.84 · 2022: $416 · 2023: $502 · 2024: $354 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $443.61 | 2019-2025 | Liletta, Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $209.92 | 2021-2025 | Acessa Provu System, Coolseal Generator, Novasure |
| Exeltis, USA INC. | $175.95 | 2023-2025 | Slynd |
| Mayne Pharma Commercial LLC | $171.11 | 2021-2025 | |
| Biogen, INC. | $136.83 | 2025 | Zurzuvae |
| Pfizer INC. | $109.77 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $104.72 | 2023-2025 | Myfembree |
| Evofem Biosciences, INC. | $104.64 | 2022-2025 | Solosec, Phexx, Phexxi |
| Merck Sharp & Dohme LLC | $86.28 | 2019-2025 | Gardasil 9, Gardasil |
| Millicent US INC | $73.56 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Myriad Women'S Health, INC. | $73.54 | 2023 | Myrisk |
| Organon LLC | $59.90 | 2021-2025 | Nexplanon |
| Astellas Pharma US INC | $45.98 | 2024 | Veozah |
| Coopersurgical, INC. | $44.40 | 2024-2025 | Paragard T 380a |
| Dexcom, INC. | $42.04 | 2025 | Dexcom G6 Transmitter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $32.03 | 2019-2020 | |
| Lupin INC. | $27.71 | 2019-2021 | |
| Avion Pharmaceuticals | $27.70 | 2019-2022 | |
| Mylan Pharmaceuticals INC. | $24.79 | 2019 | |
| Exact Sciences Corporation | $24.34 | 2024 | Cologuard Collection Kit |
| Davol INC. | $21.72 | 2025 | Arista |
| Aspira Women'S Health INC | $21.18 | 2024 | Ova1 |
| Pacira Pharmaceuticals Incorporated | $18.73 | 2023 | Exparel |
| Amag Pharmaceuticals, INC. | $18.40 | 2019 | |
| Daiichi Sankyo INC. | $16.84 | 2019 | |
| Smith+Nephew, INC. | $16.69 | 2023 | Pico |
| Convatec INC. | $16.44 | 2023 | |
| Becton, Dickinson and Company | $15.73 | 2025 | Arista |
| Agile Therapeutics, INC. | $15.67 | 2021 | |
| Shield Therapeutics INC | $14.85 | 2023 | Accrufer |
| Avanos Medical | $14.10 | 2019 | |
| Meditrina | $12.70 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Villa Olvera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.